Yale-linked Vera has rebranded from Trucode Gene Repair and will use the money to move towards clinical trials.

Vera Therapeutics, a US-based immunological and inflammatory disease therapy producer spun out of Yale University, has secured $80m of series C funding from investors including Alphabet’s early-stage corporate venturing unit GV. The round was led by venture capital firm Abingworth and also attracted financial services group Fidelity Management & Research Company in addition to Alexandria…

The rest of this content is only accessible to University Venturing: News, Data and Events - Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.